Yongyue Wei1,2,3, Paula Tejera1, Zhaoxi Wang1, Ruyang Zhang1,2, Feng Chen2,3, Li Su1, Xihong Lin4, Ednan K Bajwa5, B Taylor Thompson5, David C Christiani1,3,5. 1. 1 Department of Environmental Health and. 2. 2 Department of Biostatistics, School of Public Health and. 3. 3 China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China; and. 4. 4 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. 5. 5 Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
RATIONALE: Platelets are believed to contribute to acute respiratory distress syndrome (ARDS) pathogenesis through inflammatory coagulation pathways. We recently reported that leucine-rich repeat-containing 16A (LRRC16A) modulates baseline platelet counts to mediate ARDS risk. OBJECTIVES: To examine the role of LRRC16A in ARDS survival and its mediating effect through platelets. METHODS: A total of 414 cases with ARDS from intensive care units (ICUs) were recruited who had exome-wide genotyping data, detailed platelet counts, and follow-up data during ICU hospitalization. Association of LRRC16A single-nucleotide polymorphisms (SNPs) and ARDS prognosis, and the mediating effect of SNPs through platelet counts were analyzed. LRRC16A mRNA expression levels for 39 cases with ARDS were also evaluated. MEASUREMENTS AND MAIN RESULTS: Missense SNP rs9358856G>A within LRRC16A was associated with favorable survival within 28 days (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.38-0.87; P = 0.0084) and 60 days (P = 0.0021) after ICU admission. Patients with ARDS who carried the variant genotype versus the wild-type genotype showed an attenuated platelet count decline (∆PLT) within 28 days (difference of ∆PLT, -27.8; P = 0.025) after ICU admission. Patients with ∆PLT were associated with favorable ARDS outcomes. Mediation analysis indicated that the SNP prognostic effect was mediated through ∆PLT within 28 days (28-day survival: HRIndirect, 0.937; 95% CI, 0.918-0.957; P = 0.0009, 11.53% effects mediated; 60-day survival: HRIndirect, 0.919; 95% CI, 0.901-0.936; P = 0.0001, 14.35% effects mediated). Functional exploration suggested that this SNP reduced LRRC16A expression at ICU admission, which was associated with a lesser ∆PLT during ICU hospitalization. CONCLUSIONS: LRRC16A appears to mediate ∆PLT after ICU admission to affect the prognosis in patients with ARDS.
RATIONALE: Platelets are believed to contribute to acute respiratory distress syndrome (ARDS) pathogenesis through inflammatory coagulation pathways. We recently reported that leucine-rich repeat-containing 16A (LRRC16A) modulates baseline platelet counts to mediate ARDS risk. OBJECTIVES: To examine the role of LRRC16A in ARDS survival and its mediating effect through platelets. METHODS: A total of 414 cases with ARDS from intensive care units (ICUs) were recruited who had exome-wide genotyping data, detailed platelet counts, and follow-up data during ICU hospitalization. Association of LRRC16A single-nucleotide polymorphisms (SNPs) and ARDS prognosis, and the mediating effect of SNPs through platelet counts were analyzed. LRRC16A mRNA expression levels for 39 cases with ARDS were also evaluated. MEASUREMENTS AND MAIN RESULTS: Missense SNP rs9358856G>A within LRRC16A was associated with favorable survival within 28 days (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.38-0.87; P = 0.0084) and 60 days (P = 0.0021) after ICU admission. Patients with ARDS who carried the variant genotype versus the wild-type genotype showed an attenuated platelet count decline (∆PLT) within 28 days (difference of ∆PLT, -27.8; P = 0.025) after ICU admission. Patients with ∆PLT were associated with favorable ARDS outcomes. Mediation analysis indicated that the SNP prognostic effect was mediated through ∆PLT within 28 days (28-day survival: HRIndirect, 0.937; 95% CI, 0.918-0.957; P = 0.0009, 11.53% effects mediated; 60-day survival: HRIndirect, 0.919; 95% CI, 0.901-0.936; P = 0.0001, 14.35% effects mediated). Functional exploration suggested that this SNP reduced LRRC16A expression at ICU admission, which was associated with a lesser ∆PLT during ICU hospitalization. CONCLUSIONS:LRRC16A appears to mediate ∆PLT after ICU admission to affect the prognosis in patients with ARDS.
Authors: Yongyue Wei; Zhaoxi Wang; Li Su; Feng Chen; Paula Tejera; Ednan K Bajwa; Mark M Wurfel; Xihong Lin; David C Christiani Journal: Chest Date: 2015-03 Impact factor: 9.410
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia Journal: Antioxid Redox Signal Date: 2019-06-18 Impact factor: 8.401
Authors: William Bain; Tolani Olonisakin; Minting Yu; Yanyan Qu; Mei Hulver; Zeyu Xiong; Huihua Li; Joseph Pilewski; Rama K Mallampalli; Mehdi Nouraie; Anuradha Ray; Prabir Ray; Zhenyu Cheng; Robert M Q Shanks; Claudette St Croix; Roy L Silverstein; Janet S Lee Journal: Blood Adv Date: 2019-02-12
Authors: Ruyang Zhang; Zhaoxi Wang; Paula Tejera; Angela J Frank; Yongyue Wei; Li Su; Zhaozhong Zhu; Yichen Guo; Feng Chen; Ednan K Bajwa; B Taylor Thompson; David C Christiani Journal: Intensive Care Med Date: 2016-12-28 Impact factor: 17.440
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: John P Reilly; Fan Wang; Tiffanie K Jones; Jessica A Palakshappa; Brian J Anderson; Michael G S Shashaty; Thomas G Dunn; Erik D Johansson; Thomas R Riley; Brian Lim; Jason Abbott; Caroline A G Ittner; Edward Cantu; Xihong Lin; Carmen Mikacenic; Mark M Wurfel; David C Christiani; Carolyn S Calfee; Michael A Matthay; Jason D Christie; Rui Feng; Nuala J Meyer Journal: Intensive Care Med Date: 2018-10-21 Impact factor: 17.440